Genetic Testing vs. AI-Based Risk Assessment: What's the Difference?

There are now two very different ways to understand your breast cancer risk before any cancer appears. One looks at your inherited DNA, and the other looks at your breast tissue using artificial intelligence (AI). Both can be valuable, and they answer different questions.

This guide explains how genetic testing and AI-based risk assessment work, how they differ, and how to decide which one, or both, might be right for you.

Genetic testing analyzes your DNA, usually from a blood or saliva sample, to look for inherited mutations that raise cancer risk.¹ The best known are mutations in the BRCA1 and BRCA2 genes, but modern multigene panels also check genes such as PALB2, CHEK2, ATM, and TP53.²

Inherited mutations are relatively uncommon. Only about 5% to 10% of all breast cancers are hereditary, and BRCA1 or BRCA2 mutations account for roughly 2% to 3% of cases. But for the people who carry them, the risk is high: an estimated 55% to 72% of women with a BRCA1 mutation and 45% to 69% of women with a BRCA2 mutation develop breast cancer in their lifetime.¹

A newer approach called a polygenic risk score looks at many common genetic variants that each add a small amount to risk. Unlike BRCA testing, which applies mainly to people with strong family history, polygenic scores can estimate genetic risk more broadly across the population.³

AI-based risk assessment does not look at your genes at all. Instead, it uses artificial intelligence to analyze a routine mammogram and detect subtle tissue patterns that predict future breast cancer, even when the image looks normal.⁴

In 2025, the U.S. Food and Drug Administration authorized Clairity Breast, the first AI tool cleared to estimate a woman's five-year breast cancer risk from a standard mammogram.⁴ A 2024 study in the Journal of the American College of Radiology suggests image-based AI models can be more accurate than traditional risk tools, reaching an accuracy score (AUC) around 0.72 compared with 0.61 for models based on breast density or clinical factors.⁵

The two approaches differ in what they measure and who they help most:

• What they look at. Genetic testing reads your inherited DNA; AI risk assessment reads your breast tissue on a mammogram.^1,4

• Who they apply to. Genetic testing is most useful for people with a personal or family history that raises concern, while AI risk assessment can be run on any woman already getting mammograms.^2,4

• Time frame. Genetic results reflect lifetime risk, while AI tools typically estimate risk over the next five years.⁴

• What they cannot tell you. Genetic testing does not read your current breast tissue, and AI risk assessment does not detect inherited mutations.

For many people, the answer is not either-or. Consider genetic testing if you have⁶:

• A close relative with breast cancer diagnosed at a young age

• Multiple relatives with breast, ovarian, pancreatic, or prostate cancer

• A known inherited mutation in the family

• Ashkenazi Jewish ancestry, which carries a higher chance of BRCA mutations

AI-based risk assessment, by contrast, may be worth asking about any time you have a mammogram, since it adds a layer of insight from the image itself, particularly for women whose risk is underestimated by traditional models.⁵

Genetic testing and AI risk assessment are complementary, not competing. Genetics reveals inherited predisposition that can span your whole life, while AI reveals what your breast tissue suggests about your nearer-term risk. Used together, they give you and your doctor a fuller picture, which can inform decisions about when to start screening, how often to screen, and whether to add tests like breast MRI.

If you have a family history of breast or related cancers, ask your doctor whether genetic counseling and testing make sense for you. A genetic counselor can help you understand which test to consider and what the results would mean. And when you have your next mammogram, ask whether AI-based risk assessment is available. Either way, your provider can help you turn the results into a personalized plan.

No. A BRCA test looks for inherited gene mutations in your DNA, while an AI risk test analyzes your mammogram image to estimate future risk.^1,4 They measure different things and can be used together.

Most people without a family history or other risk factors do not meet the criteria for BRCA testing, since inherited mutations are uncommon.¹ Your doctor or a genetic counselor can help determine whether testing is appropriate for you.⁶

No. AI risk assessment does not detect inherited mutations, so it cannot replace genetic testing for people who need it. The two provide different information.

Coverage varies. Genetic testing is often covered when you meet specific criteria, and coverage for AI-based risk assessment is still evolving. Check with your provider and insurer.

Whether you learn about your risk through your genes or your mammogram, the goal is the same: catching cancer as early as possible, when it is most treatable. And while genetic testing typically starts with a referral, the AI side of the picture is something you can pursue now.

The Clairity Breast™ Cancer 5-Year Risk Assessment, available through Everlywell, uses FDA-authorized AI-driven software to analyze a routine screening mammogram from the last 12 months and estimate your personalized five-year breast cancer risk. Provider-reviewed results are delivered to your My Everly account with guideline-based information to review with your health care provider, who may use your risk score alongside your family history and any genetic results to personalize your screening plan. Clairity Breast estimates future risk; it does not detect or diagnose cancer, does not test for inherited mutations, and is not a substitute for mammograms or ongoing care with your provider.

Talk with your doctor about which risk tools fit your history and your goals, and keep up with your recommended screenings. Everlywell is here to help you stay proactive about your health.